SCHEMBL6439732

SCHEMBL6439732

CCc1nc2ccccc2n1-c1ccc(O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 6/20 0.61
ESR1 P03372 5/20 0.61
GRIA1 P42261 1/20 0.56
CACNG8 Q8WXS5 1/20 0.56
CACNG2 Q9Y698 1/20 0.56
MAPK1 P28482 3/20 0.51
LMNA P02545 1/20 0.51
HTT P42858 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
ALDH1A1 P00352 2/20 0.48
CYP1A2 P05177 1/20 0.47
PDE10A Q9Y233 1/20 0.47
KDM4E B2RXH2 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
POLB P06746 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10816506 0.87 L3MBTL1 (0.55) MAPK1LMNAHTTMEN1KMT2A
SCHEMBL762447 0.87 MAPK1 (0.66) ESR2ESR1MAPK1HTTMEN1
SCHEMBL7150527 0.85 LMNA (0.70) ESR2ESR1GRIA1CACNG8CACNG2
SCHEMBL10819080 0.84 RAB9A (0.61) GRIA1CACNG8CACNG2MAPK1LMNA
SCHEMBL10816372 0.84 SMN1; SMN2 (0.52) ESR2ESR1MAPK1LMNAHTT
SCHEMBL10816952 0.84 HTT (0.50) ESR2ESR1MAPK1LMNAHTT
SCHEMBL29527273 0.84 HTT (0.50) ESR2ESR1MAPK1LMNAHTT
SCHEMBL18815961 0.84 MAPK1 (0.46) ESR2ESR1MAPK1HTTMEN1
SCHEMBL1624977 0.82 NTRK1 (0.52) ESR2ESR1MAPK1LMNAHTT
SCHEMBL3948783 0.82 NTRK1 (0.48) ESR2ESR1MAPK1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1517897-A2 BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS Pfizer Products Inc. (US) 2005-03-30 EP disclosed
US-20040002524-A1 Benzimidazole compounds and their use as estrogen agonists/antagonists CHESWORTH RICHARD (US) 2004-01-01 US disclosed
WO-2004000817-A2 BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS PFIZER PRODUCTS INC. (US) 2003-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002524-A1 Benzimidazole compounds and their use as estrogen agonists/antagonists ESR1, GPER1, ESR2 ESR2 3/4885ESR1 1/4885GRIA1 1481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.